Chronic treatment with GLP-2 (3–33), a competitive GLP-2R antagonist [85], also reportedly exacerbates dyslipidemia and hepatic lipid accumulation in HFD-fed mice [86], suggesting that endogenous GLP-2 may have a defensive role acting against lipid imbalance under conditions of obesity. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.